

Elai Davicioni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1981520/publications.pdf>

Version: 2024-02-01

159
papers

11,724
citations

26567

56
h-index

30848

102
g-index

162
all docs

162
docs citations

162
times ranked

13702
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 544-554.	0.9	638
2	The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. <i>Nature Genetics</i> , 2013, 45, 1392-1398.	9.4	601
3	Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy. <i>PLoS ONE</i> , 2013, 8, e66855.	1.1	524
4	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. <i>Nature Communications</i> , 2014, 5, 5383.	5.8	522
5	Translational Activation of Snail1 and Other Developmentally Regulated Transcription Factors by YB-1 Promotes an Epithelial-Mesenchymal Transition. <i>Cancer Cell</i> , 2009, 15, 402-415.	7.7	400
6	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2014, 15, 1521-1532.	5.1	291
7	Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar Rhabdomyosarcomas. <i>Cancer Research</i> , 2006, 66, 6936-6946.	0.4	286
8	Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population. <i>Journal of Urology</i> , 2013, 190, 2047-2053.	0.2	280
9	Molecular Classification of Rhabdomyosarcoma—Genotypic and Phenotypic Determinants of Diagnosis. <i>American Journal of Pathology</i> , 2009, 174, 550-564.	1.9	271
10	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. <i>Lancet Oncology</i> , The, 2014, 15, 1469-1480.	5.1	226
11	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	3.4	219
12	Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. <i>European Urology</i> , 2016, 69, 157-165.	0.9	206
13	Genomic Classifier Identifies Men With Adverse Pathology After Radical Prostatectomy Who Benefit From Adjuvant Radiation Therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 944-951.	0.8	196
14	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1612-1620.	5.1	182
15	Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy Cohort. <i>European Urology</i> , 2015, 67, 326-333.	0.9	178
16	Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. <i>Journal of Clinical Oncology</i> , 2017, 35, 1991-1998.	0.8	176
17	FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. <i>Nature</i> , 2019, 571, 408-412.	13.7	163
18	A Genomic Classifier Improves Prediction of Metastatic Disease Within 5 Years After Surgery in Node-negative High-risk Prostate Cancer Patients Managed by Radical Prostatectomy Without Adjuvant Therapy. <i>European Urology</i> , 2015, 67, 778-786.	0.9	162

#	ARTICLE	IF	CITATIONS
19	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-590.	0.8	162
20	Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 1038-1046.	0.4	149
21	DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. <i>Cancer Cell</i> , 2015, 28, 97-113.	7.7	148
22	Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. <i>Cancer Research</i> , 2016, 76, 4948-4958.	0.4	147
23	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2019, 111, 301-310.	3.0	142
24	Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. <i>Urology</i> , 2016, 90, 148-152.	0.5	138
25	The Homeoprotein Six1 Transcriptionally Activates Multiple Protumorigenic Genes but Requires Ezrin to Promote Metastasis. <i>Cancer Research</i> , 2006, 66, 1982-1989.	0.4	132
26	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. <i>EBioMedicine</i> , 2018, 31, 182-189.	2.7	132
27	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 701-710.	0.9	128
28	Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2789-2796.	0.8	127
29	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. <i>Cancer Cell</i> , 2019, 35, 401-413.e6.	7.7	127
30	Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. <i>European Urology</i> , 2015, 68, 555-567.	0.9	125
31	Prostate cancer radiomics and the promise of radiogenomics. <i>Translational Cancer Research</i> , 2016, 5, 432-447.	0.4	111
32	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. <i>Nature Communications</i> , 2019, 10, 4358.	5.8	109
33	The lncRNAs <i>PCGEM1</i> and <i>PRNCR1</i> are not implicated in castration resistant prostate cancer. <i>Oncotarget</i> , 2014, 5, 1434-1438.	0.8	106
34	Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 1304-1311.	0.8	102
35	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. <i>Cell Reports</i> , 2017, 19, 2045-2059.	2.9	99
36	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. <i>Cancer Research</i> , 2017, 77, 1021-1034.	0.4	94

#	ARTICLE	IF	CITATIONS
37	Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. <i>Oncotarget</i> , 2016, 7, 53362-53376.	0.8	90
38	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. <i>Clinical Cancer Research</i> , 2017, 23, 7072-7083.	3.2	87
39	Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1107-1119.	3.0	85
40	The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management. <i>European Urology</i> , 2019, 76, 546-559.	0.9	82
41	Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5082-5093.	3.2	82
42	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 544.	3.4	82
43	Quantitative Expression Profiling in Formalin-Fixed Paraffin-Embedded Samples by Affymetrix Microarrays. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 409-417.	1.2	81
44	Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. <i>European Urology</i> , 2016, 70, 14-17.	0.9	79
45	Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. <i>European Urology</i> , 2017, 72, 845-852.	0.9	79
46	Gene Expression Profiling for Survival Prediction in Pediatric Rhabdomyosarcomas: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 1240-1246.	0.8	78
47	Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1009-1024.	1.1	77
48	Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. <i>Journal of Clinical Oncology</i> , 2017, 35, 1982-1990.	0.8	76
49	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6721-6730.	3.2	74
50	LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. <i>Cancer Research</i> , 2017, 77, 5479-5490.	0.4	71
51	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3908-3920.	3.2	71
52	Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. <i>European Urology</i> , 2016, 70, 588-596.	0.9	69
53	Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PROIMPACT study. <i>Cancer</i> , 2017, 123, 2850-2859.	2.0	66
54	Lipid degradation promotes prostate cancer cell survival. <i>Oncotarget</i> , 2017, 8, 38264-38275.	0.8	64

#	ARTICLE	IF	CITATIONS
55	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. <i>European Urology</i> , 2018, 73, 524-532.	0.9	60
56	Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer. <i>European Urology</i> , 2017, 71, 257-266.	0.9	59
57	Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. <i>Oncotarget</i> , 2013, 4, 600-609.	0.8	58
58	Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. <i>BMC Cancer</i> , 2017, 17, 759.	1.1	57
59	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 5619-5629.	3.2	56
60	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. <i>Nature Communications</i> , 2022, 13, 2559.	5.8	56
61	The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. <i>European Urology</i> , 2018, 74, 444-452.	0.9	55
62	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. <i>European Urology</i> , 2018, 74, 107-114.	0.9	54
63	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. <i>GigaScience</i> , 2018, 7, .	3.3	54
64	Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. <i>European Urology</i> , 2018, 73, 168-175.	0.9	53
65	Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 399-405.	2.0	53
66	Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. <i>BJU International</i> , 2015, 115, 419-429.	1.3	52
67	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 2450-2457.	3.2	52
68	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 7349.	5.8	51
69	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. <i>Communications Biology</i> , 2021, 4, 670.	2.0	50
70	Inferring cancer subnetwork markers using density-constrained biclustering. <i>Bioinformatics</i> , 2010, 26, i625-i631.	1.8	49
71	Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14977-14982.	3.3	49
72	Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. <i>Cancer Research</i> , 2019, 79, 3636-3650.	0.4	47

#	ARTICLE	IF	CITATIONS
73	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. <i>Oncotarget</i> , 2017, 8, 18949-18967.	0.8	47
74	Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	46
75	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 471.	3.4	46
76	Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 395-406.	1.2	46
77	The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1777-1786.	3.2	42
78	Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. <i>European Urology</i> , 2019, 76, 200-206.	0.9	41
79	SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. <i>Journal of Urology</i> , 2016, 196, 1436-1444.	0.2	38
80	An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. <i>European Urology</i> , 2017, 72, 142-150.	0.9	38
81	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. <i>Clinical Cancer Research</i> , 2019, 25, 4290-4299.	3.2	38
82	Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. <i>Genome Medicine</i> , 2019, 11, 60.	3.6	36
83	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 84-91.	0.4	36
84	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 136-143.	2.0	36
85	Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1. <i>Oncotarget</i> , 2016, 7, 24326-24338.	0.8	33
86	Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures. <i>Journal of Urology</i> , 2016, 196, 1036-1041.	0.2	33
87	Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting. <i>Journal of Urology</i> , 2016, 195, 1748-1753.	0.2	33
88	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. <i>Journal of Urology</i> , 2017, 197, 122-128.	0.2	33
89	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 826-836.	0.8	33
90	Retinoic acid induces leukemia cell G 1 arrest and transition into differentiation by inhibiting cyclinâ€dependent kinaseâ€activating kinase binding and phosphorylation of PML/RAR. <i>FASEB Journal</i> , 2006, 20, 2142-2144.	0.2	32

#	ARTICLE	IF	CITATIONS
91	Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 295-302.	2.0	30
92	Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 448-458.	3.2	29
93	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. <i>Oncotarget</i> , 2017, 8, 50804-50813.	0.8	29
94	Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	1.5	29
95	Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e299-e309.	0.9	25
96	Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 883-891.	1.2	24
97	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2018, 24, 3908-3916.	3.2	24
98	Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. <i>Cancer Research</i> , 2015, 75, 4322-4334.	0.4	23
99	Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. <i>European Urology</i> , 2016, 69, 496-504.	0.9	23
100	Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level. <i>Journal of Urology</i> , 2018, 200, 1241-1249.	0.2	23
101	Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. <i>European Radiology</i> , 2019, 29, 4861-4870.	2.3	23
102	Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 419-428.	2.0	22
103	Diagnostic and Prognostic Sarcoma Signatures. <i>Molecular Diagnosis and Therapy</i> , 2008, 12, 359-374.	1.6	21
104	Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 1005.	3.4	21
105	Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. <i>BJU International</i> , 2015, 116, 556-567.	1.3	19
106	Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. <i>European Urology Oncology</i> , 2019, 2, 589-596.	2.6	19
107	Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. <i>Practical Radiation Oncology</i> , 2020, 10, e82-e90.	1.1	19
108	Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit. <i>European Urology Focus</i> , 2018, 4, 540-546.	1.6	18

#	ARTICLE	IF	CITATIONS
109	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	0.9	18
110	Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube. <i>Transgenic Research</i> , 2006, 15, 595-614.	1.3	17
111	Genomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers. <i>Frontiers in Genetics</i> , 2012, 3, 23.	1.1	17
112	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 646-653.	2.0	17
113	Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	17
114	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. <i>European Urology</i> , 2021, 80, 149-159.	0.9	17
115	G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer. <i>Nature Communications</i> , 2021, 12, 6662.	5.8	17
116	Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis. <i>Research and Reports in Urology</i> , 2016, Volume 8, 77-84.	0.6	16
117	Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 475-484.	1.2	16
118	Whole-Transcriptome Profiling of Thyroid Nodules Identifies Expression-Based Signatures for Accurate Thyroid Cancer Diagnosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4072-4079.	1.8	15
119	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 262-268.	0.8	15
120	Transcriptome-Wide Detection of Differentially Expressed Coding and Non-Coding Transcripts and Their Clinical Significance in Prostate Cancer. <i>Journal of Oncology</i> , 2012, 2012, 1-11.	0.6	14
121	<i>AXIN2</i> expression predicts prostate cancer recurrence and regulates invasion and tumor growth. <i>Prostate</i> , 2016, 76, 597-608.	1.2	14
122	Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 955-962.	2.6	14
123	Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 171-182.	3.2	14
124	A comparative study of PCS and PAM50 prostate cancer classification schemes. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 733-742.	2.0	14
125	ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63. <i>Prostate</i> , 2018, 78, 896-904.	1.2	13
126	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 573.e19-573.e29.	0.8	13

#	ARTICLE	IF	CITATIONS
127	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021, 79, 717-721.	0.9	13
128	Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 726-732.	0.4	11
129	Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 621-627.	0.4	10
130	Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1376-1383.	1.1	9
131	Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 19, 246-254.e5.	0.9	9
132	A transcriptomic model for homologous recombination deficiency in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 659-665.	2.0	9
133	A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies. <i>Prostate</i> , 2019, 79, 1589-1596.	1.2	8
134	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 584-590.	1.1	8
135	Genomic and clinical characterization of stromal infiltration markers in prostate cancer. <i>Cancer</i> , 2020, 126, 1407-1412.	2.0	8
136	Prognostic value of the SPOP mutant genomic subclass in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 418-422.	0.8	8
137	Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. <i>European Urology Open Science</i> , 2020, 22, 34-44.	0.2	7
138	Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. <i>European Urology Open Science</i> , 2022, 40, 19-26.	0.2	7
139	Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer. <i>Biology of the Cell</i> , 2015, 107, 232-244.	0.7	6
140	Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. <i>BJU International</i> , 2017, 119, 961-967.	1.3	6
141	Identifying and treating <i>ROBO1</i> ⁺ <i>DOCK1</i> ⁺ prostate cancer: An aggressive cancer subtype prevalent in African American patients. <i>Prostate</i> , 2020, 80, 1045-1057.	1.2	5
142	Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy. <i>Journal of Urology</i> , 2021, 205, 1344-1351.	0.2	5
143	Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer. <i>Cancers</i> , 2022, 14, 2734.	1.7	5
144	A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer. <i>Scientific Reports</i> , 2021, 11, 5849.	1.6	4

#	ARTICLE	IF	CITATIONS
145	Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2223-2231.	1.2	4
146	Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 734.e11-734.e17.	0.8	4
147	Development of a predictive model for stromal content in prostate cancer samples to improve signature performance. <i>Journal of Pathology</i> , 2019, 249, 411-424.	2.1	3
148	Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 527-541.	1.5	3
149	Genomic biomarkers to guide precision radiotherapy in prostate cancer. <i>Prostate</i> , 2022, 82, .	1.2	3
150	Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes. <i>Cancer</i> , 2017, 123, 2240-2247.	2.0	2
151	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	1.5	2
152	Predictors of Prostate-specific Membrane Antigen (PSMA/FOLH1) Expression in a Genomic Database. <i>Urology</i> , 2020, 144, 117-122.	0.5	2
153	Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 5.e1-5.e13.	0.8	2
154	High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 105-112.	2.0	2
155	2239 CLINICAL AND GENOMIC ANALYSIS OF METASTATIC DISEASE PROGRESSION IN A BACKGROUND OF BIOCHEMICAL RECURRENCE. <i>Journal of Urology</i> , 2013, 189, .	0.2	1
156	Gene Expression Correlates of Site-specific Metastasis Among Men With Lymph Node Positive Prostate Cancer Treated With Radical Prostatectomy: A Case Series. <i>Urology</i> , 2018, 112, 29-32.	0.5	1
157	Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease. <i>European Urology Focus</i> , 2020, 7, 797-806.	1.6	1
158	Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases. , 2021, 5, 50-61.		1
159	Clinical and genomic analysis of metastatic disease progression in a background of biochemical recurrence.. <i>Journal of Clinical Oncology</i> , 2012, 30, 90-90.	0.8	1